Results of systematic review s and meta-analyses of r and omized controlled trials have shown that both systemic estrogen therapy or hormone therapy ( estrogen combined with a progestin ) are useful to prevent bone loss , and they are the most effective treatment for such climacteric symptoms as hot flushes , sweating , vaginal dryness , and dyspareunia .
The combination of a SERM with estrogen as a tissue selective estrogen complex ( TSEC ) is a new strategy for the prevention of bone loss and the treatment of climacteric symptoms .
This combination is particularly interesting from a clinical point of view , taking into account that estrogen alone did not increase breast cancer risk by the Women 's Health Initiative .
TSEC is hypothesized to provide the benefits of estrogen-alone therapy , with an improved tolerability profile because the SERM component can make possible the elimination of progestin .
The conclusion is that effectively , the combination of bazedoxifene and conjugated estrogens may be a promising alternative to hormone therapy for the prevention of osteoporosis and the treatment of postmenopausal symptoms in non-hysterectomized postmenopausal women
Decreasing levels of estrogens during menopause are associated with reduced bone density and an increased risk of osteoporosis .
Many women also experience bothersome vasomotor and vaginal symptoms during the menopausal transition .
Unfortunately , estrogen therapy and hormone therapy increase the risk of endometrial and breast cancer , respectively .
The selective estrogen receptor modulators ( SERMs ) result in positive estrogenic effects on bone , with no negative effects on the endometrium and breast but do not provide relief from postmenopausal symptoms .
The objective of this review was to critically evaluate the evidence from the reports published to date on the use of bazedoxifene ( a third-generation SERM ) in combination with conjugated estrogens in postmenopausal women .
Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.
OBJECTIVE To survey the prevalence of 18 menopausal symptoms in nine ethnic groups of Asian women . To evaluate responsiveness of symptoms to three estrogen/progestin doses in Asian women . DESIGN A prospect i ve , r and omized , double-blind multinational clinical trial in 1028 healthy postmenopausal women from 11 Asian countries/regions . Following 2 weeks of baseline observations , the women received one of three conjugated estrogens (CE)/medroxyprogesterone acetate ( MPA ) doses ( in mg ) daily for 24 weeks : 0.625/2.5 ; 0.45/1.5 ; or 0.3/1.5 . At baseline and throughout the study period , the women were asked to record each symptom daily on diary cards translated into 10 language s. RESULTS The number of women in the different ethnic groups ranged from 24 ( Malay ) to 248 ( Chinese ) . The overall prevalence of symptoms differed among the groups , with Vietnamese women generally reporting the highest rates . Within each ethnic group , the prevalence of individual symptoms varied substantially . Only 5 % of Indonesian women , for example , reported hot flushes but 93 % complained of body or joint aches/pains . Overall , body or joint aches/pains was the most prevalent symptom , ranging from 76 % in Korean women to 96 % in Vietnamese women . Therapy result ed in a significant decline in all symptoms . The decline was observed with all three doses after 4 weeks of treatment and continued throughout the 6-month study period . CONCLUSION The prevalence of individual menopausal symptoms differed among ethnic groups of Asian women . Within each ethnic group the percentage of women reporting each symptom varied substantially . Symptoms declined after 4 weeks of hormone therapy and thereafter throughout the study . The effect of the lowest dose of CE/MPA ( 0.3/1.5 mg/day ) was comparable to that of the higher doses
Results of systematic review s and meta-analyses of r and omized controlled trials have shown that both systemic estrogen therapy or hormone therapy ( estrogen combined with a progestin ) are useful to prevent bone loss , and they are the most effective treatment for such climacteric symptoms as hot flushes , sweating , vaginal dryness , and dyspareunia .
The combination of a SERM with estrogen as a tissue selective estrogen complex ( TSEC ) is a new strategy for the prevention of bone loss and the treatment of climacteric symptoms .
This combination is particularly interesting from a clinical point of view , taking into account that estrogen alone did not increase breast cancer risk by the Women 's Health Initiative .
TSEC is hypothesized to provide the benefits of estrogen-alone therapy , with an improved tolerability profile because the SERM component can make possible the elimination of progestin .
The conclusion is that effectively , the combination of bazedoxifene and conjugated estrogens may be a promising alternative to hormone therapy for the prevention of osteoporosis and the treatment of postmenopausal symptoms in non-hysterectomized postmenopausal women
Decreasing levels of estrogens during menopause are associated with reduced bone density and an increased risk of osteoporosis .
Many women also experience bothersome vasomotor and vaginal symptoms during the menopausal transition .
Unfortunately , estrogen therapy and hormone therapy increase the risk of endometrial and breast cancer , respectively .
The selective estrogen receptor modulators ( SERMs ) result in positive estrogenic effects on bone , with no negative effects on the endometrium and breast but do not provide relief from postmenopausal symptoms .
The objective of this review was to critically evaluate the evidence from the reports published to date on the use of bazedoxifene ( a third-generation SERM ) in combination with conjugated estrogens in postmenopausal women .